text:
Participating Organization(s)
National Institutes of Health (NIH)
of Program Coordination, Planning and Strategic Initiatives, Office of Research
Infrastructure Programs (ORIP)
Funding Opportunity Title
Limited Competition: Specific pathogen free macaque colonies (U24)
Activity Code
U24 Resource-Related Research Projects – Cooperative Agreements
Announcement Type
Related Notices
Funding Opportunity Announcement (FOA) Number
Companion FOA
PAR-11-116, U42 Animal (Mammalian and Nonmammalian) Model, and Animal and Biological
Materials Resource Cooperative Agreements.
Catalog of Federal Domestic Assistance (CFDA) Number(s)
FOA Purpose
The purpose of this FOA is to provide continuing support for specific pathogen free (SPF) macaque colonies previously funded under the auspices of RFA-RR-02-005 (https://grants.nih.gov/grants/guide/rfa-files/RFA-RR-02-005.html). SPF macaques are free of certain viruses that can compromise the results of AIDS-related investigations or that provide a risk to personnel who handle the animals. Applicants must provide plans for: a) maintaining the SPF colonies, minimally at current levels; b) distributing animals to AIDS researchers, with first priority to NIH funded investigators; c) assaying for the presence of specific viruses; d) typing animals for specific major histocompatibility complex loci; and e) financing colony operations.
Posted Date
February 14, 2011
Letter of Intent Due Date
Not Applicable
Application Due Date(s)
Standard dates apply
AIDS Application Due Date(s)
Standard dates apply
Scientific Merit Review
Standard dates apply
Advisory Council Review
Standard dates apply
Earliest Start Date(s)
Standard dates apply
Expiration Date
(Now Expired August 16, 2013 per NOT-OD-13-100), Originally May 8, 2014
Due Dates for E.O. 12372
Not Applicable
Required Application Instructions
It is critical that applicants follow the instructions in the PHS398 Application Guide except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. While some links are provided, applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.
Part 1. Overview Information
Part 2. Full Text of Announcement
Section I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information
The NIH funds a vigorous HIV/AIDS research program to study the basic biology of HIV and related complications, as well as to develop and test new therapies and approaches to prevention, such as vaccines and microbicides. Macaque monkeys are physiologically and genetically similar to humans and thus provide useful models to facilitate many aspects of AIDS research. For example, rhesus macaques (Macaca mulata) infected with the Simian Immunodeficiency Virus [SIV – the non human primate (NHP) equivalent of human HIV] are used to examine many aspects of viral pathogenesis, including early events not readily studied in human patients. Macaques are also used to investigate concepts for the development of AIDS vaccines and microbicides before testing in human subjects.
The presence of certain viruses in the monkey experimental subject can compromise the ability to interpret the results of AIDS-related investigations. Accordingly, in the year 2000, the NCRR-funded cooperative agreements using the U42 mechanism to develop specific pathogen free (SPF) macaque colonies (RFA-00-004, https://grants.nih.gov/grants/guide/rfa-files/RFA-RR-00-004.html). The program was expanded in 2002 to fund additional SPF macaque colonies using the U24 cooperative agreement mechanism (RFA-02-005, https://grants.nih.gov/grants/guide/rfa-files/RFA-RR-02-005.html). Collectively, these colonies comprise a consortium of NCRR-funded resources that provide SPF macaques for AIDS research.
The SPF macaques are free of (antibody negative for): SIV, Type D simian retrovirus (SRV) and simian T-lyphotropic virus (STLV-1). The SPF animals are also required to be free of herpes B virus, which does not appear to affect the results of AIDS-related investigations, but is a potential health risk for personnel handling the animals. The major emphasis has been on the production of SPF Indian origin rhesus macaques, which are a preferred model to study the entire course of SIV infection, leading to AIDS. The SPF cooperative agreements have also supported smaller numbers of SPF Chinese origin rhesus and pigtail macaques (Macaca nemestrina), which have specialized uses for various aspects of AIDS research, such as development of microbicides. Finally, some investigators have derived sub colonies of macaques that are SPF for additional viruses, such as herpes viruses. These expanded SPF animals are used for investigations of, for example, herpes virus coinfection or activation of latent herpes viruses.
SPF macaques are also characterized in regard to certain major histocompatibility (MHC) types. An important aspect of the evaluation of AIDS vaccines in NHPs and in humans is the measurement of virus-specific T-cell immune responses. The majority of immunogenic cytotoxic T lymphocytes bind to MHC class I molecules. Certain MHC Class I alleles such as Mamu-A*01 and Mamu-B*08 are associated with slow disease progression in rhesus macaques. It is therefore important when designing an experiment to know if an animal subject harbors the particular MHC alleles that can affect the immune response to SIV infection. Determining which MHC loci have these effects is an ongoing process within the research community.
Most of the SPF macaque resources are now "closed" colonies that do not take in new animals. These colonies derive animals for investigations strictly through the breeding stock that has been developed using the U42 and U24 cooperative agreements. Overall in 2010, the SPF macaque colonies comprised approximately 6000 animals, with the capability of assigning approximately 1000 animals for use in AIDS research.
The purpose of this FOA is to support those colonies originally funded through the U24 mechanism so that they can continue to provide animals for AIDS researchers, with attendant knowledge of critical MHC genotypes in the animals. Specifically, grantees responding to this FOA must:
Funding Instrument
Cooperative Agreement: A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, scientific or program staff will assist, guide, coordinate, or participate in project activities.
Application Types Allowed
The OER Glossary and the PHS398 Application Guide provide details on these application types.
Funds Available and Anticipated Number of Awards
The number of awards is contingent upon NIH appropriations, and the submission of a sufficient number of meritorious applications.
Award Budget
The direct costs requested for the first year of the renewal or resubmission application cannot exceed 110% of the direct costs for the last year in which the cooperative agreement was previously funded.
Award Project Period
The scope of the proposed project should determine the project period. The maximum period is 4 years.
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.
Higher Education Institutions:
The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
Nonprofits Other Than Institutions of Higher Education
Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Foreign (non-U.S.) components of U.S. Organizations are not allowed.
Applicant organizations must complete the following registrations as described in the PHS398 Application Guide to be eligible to apply for or receive an award. Applicants must have a valid Dun and Bradstreet Universal Numbering System (DUNS) number in order to begin each of the following registrations.
All Program Directors/Principal Investigators (PD/PIs) must also work with their institutional officials to register with the eRA Commons or ensure their existing eRA Commons account is affiliated with the eRA Commons account of the applicant organization.
All registrations must be completed by the application due date. Applicant organizations are strongly encouraged to start the registration process at least four (4) weeks prior to the application due date.
Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Project Director/Principal Investigator (PD/PI) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.
Multiple PD/PIs are not allowed.
This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
Only one application per organization is permitted.
NIH will not accept any application in response to this FOA that is essentially the same as one currently pending initial peer review unless the applicant withdraws the pending application. NIH will not accept any application that is essentially the same as one already reviewed. Resubmission applications may be submitted, according to the NIH Policy on Resubmission Applications from the PHS398 Application Guide.
Applicants are required to prepare applications according to the current PHS 398 application forms in accordance with the PHS 398 Application Guide.
It is critical that applicants follow the instructions in the PHS398 Application Guide, except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
Applications must be prepared using the PHS 398 research
grant application forms and instructions for preparing a research grant
application. Submit a signed, typewritten original of the application, including
the checklist, and three signed photocopies in one package to:
Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710 (U.S. Postal Service Express or regular mail)
Bethesda, MD 20817 (for express/courier service; non-USPS service)
At the time of submission, two additional paper copies of the application and all copies of the appendix files must be sent to:
Bonnie B. Dunn, Ph.D.
Office of Review
National Center for Research Resources
National Institutes of Health
6701 Democracy Blvd., Room 1066
Bethesda, MD 20892-4874
Courier service zip code 20817
301-435-0824 (direct line)
301-480-3660 (fax)
E-mail: email@example.com
All page limitations described in the PHS398 Application Guide must be followed, with the following exceptions or additional requirements:
Research Strategy section is limited to 12 pages.
All instructions in the PHS398 Application Guide must be followed, with the following additional instructions:
Provide a table within the Research Strategy section that shows how colony operations are currently funded, including support from: the current U24 cooperative agreement, Program Income, and other sources such as institutional funds, if applicable. Program Income is defined as gross income earned by the recipient that is directly generated or earned as a result of the award.
Provide a financial plan within the Research Strategy section of the application. Different colonies have grown at various rates and have accumulated different numbers of animals for breeding. Therefore, colonies may be at various stages in regard to the amount of Program Income that can be generated, which depends on the size and fecundity of the colony. Regardless of the current baseline, the plan should provide a strategy for Year 2 of the renewal period such that Program Income and/or Institutional commitment, if applicable, equals at least 50% of the amount of direct costs requested for Year 2. The sum of the direct costs requested plus Program Income and Institutional commitment, if applicable, should equal the costs associated with all the functinos of the SPF colony. The same requirement applies for each of Years 3 and 4 of the renewal period. Support for the colony from sources other than the cooperative agreement and Program Income is not required. The requirement for support in addition to that provided by the Cooperative Agreement can be waived by the NCRR Program Director in exceptional circumstances.
Resource Sharing Plan
Individuals are required to comply with the instructions for the Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, and Genome Wide Association Studies (GWAS) as provided in the PHS398 Application Guide, with the following modifications:
Appendices are not allowed. If appendix material is included, the application will not be reviewed.
Part I. Overview Information contains information about Key Dates.
Information on the process of receipt and determining if
your application is considered "on-time" is described in detail in the PHS398
Application Guide.
Applicants may track the status of the application in the eRA Commons, NIH's electronic system for grants administration.
This initiative is not subject to intergovernmental review.
All NIH awards are subject to the terms and conditions, cost
principles, and other considerations described in the NIH Grants Policy
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
Applications must be postmarked on or before the due dates
in Part I. Overview Information. If an application is received after that date, it will not be reviewed.
Upon receipt, applications will be evaluated for completeness by the Center for Scientific Review , NIH. Applications that are incomplete will not be reviewed.
Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact NIH program staff at least 6 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request $500,000 or More in Direct Costs as described in the PHS398 Application Guide.
Applicants are required to follow the instructions for post-submission materials, as described in NOT-OD-10-115,
Only the review criteria described below will be considered
in the review process. As part of the NIH mission,
all applications submitted to the NIH in support of biomedical and behavioral
research are evaluated for scientific and technical merit through the NIH peer
review system.
Reviewers will provide an overall impact/priority score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).
Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
Are the PD/PIs, collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
Are the overall strategy, methodology, and analyses
well-reasoned and appropriate to accomplish the specific aims of the project? Are potential problems, alternative strategies, and benchmarks for success presented?
If the project is in the early stages of development, will the strategy
establish feasibility and will particularly risky aspects be managed?
If the project involves clinical research, are the plans for 1) protection of human subjects from research risks, and 2) inclusion of minorities and members of both sexes/genders, as well as the inclusion of children, justified in terms of the scientific goals and research strategy proposed?
Will the plans for colony management allow for provision of SPF animals of defined MHC type to AIDS researchers? Will the plans to provide animals to researchers allocate animals on a first come first served basis, with first priority to AIDS researchers funded by the NIH?
Are the proposed plans for viral testing adequate to assure that animals are free of SIV, SRV, STLV-1 and herpes B virus? Are plans for MHC typing state of the art? If an expanded SPF component is proposed, are the plans for viral testing adequate to assure that animals are free of the indicated viruses? If an expanded SPF component is proposed, is it well justified?
Does the financial plan for each of years 2, 3 and 4 of the renewal include a component comprised of Program Income and/or Institutional commitment, if applicable, that equals at least 50% of the amount of direct costs requested for the given year? Is it likely that the financial plan will meet the stated objectives?
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact/priority score, but will not give separate scores for these items.
Protections for Human Subjects
For research that involves human subjects but does
not involve one of the six categories of research that are exempt under 45 CFR
Part 46, the committee will evaluate the justification for involvement of human
subjects and the proposed protections from research risk relating to their
participation according to the following five review criteria: 1) risk to
subjects, 2) adequacy of protection against risks, 3) potential benefits to the
subjects and others, 4) importance of the knowledge to be gained, and 5) data
and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Human Subjects Protection and Inclusion Guidelines.
Inclusion of Women, Minorities, and Children
When the proposed project involves clinical research, the committee will evaluate the proposed plans for inclusion of minorities and members of both genders, as well as the inclusion of children. For additional information on review of the Inclusion section, please refer to the Human Subjects Protection and Inclusion Guidelines.
Vertebrate Animals
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.
For Renewals, the committee will consider the progress made in the last funding period.
For Revisions, the committee will consider the appropriateness of the proposed expansion of the scope of the project. If the Revision application relates to a specific line of investigation presented in the original application that was not for recommended approval by the committee, then the committee will consider whether the responses to comments from the previous scientific review group are adequate and whether substantial changes are clearly evident.
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact/priority score.
Applications from Foreign Organizations
Not Applicable.
Select Agent Research
Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Resource Sharing Plans
Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) Data Sharing Plan; 2) Sharing Model Organisms; and 3) Genome Wide Association Studies (GWAS).
Budget and Period of Support
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
Applications will be evaluated for scientific and technical
merit by (an) appropriate Scientific Review Group(s)convened by the NCRR (assignments will be shown in the eRA Commons), in accordance with NIH peer
review policy and procedures, using the stated review
As part of the scientific peer review, all applications:
Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center and will compete for available funds with all other recommended applications. Following initial peer review, recommended applications will receive a second level of review by the National Advisory Research Resources Council . The following will be considered in making funding decisions:
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons.
Information regarding the disposition of applications is available in the NIH Grants Policy Statement.
If the application is under consideration for funding, NIH
will request "just-in-time" information from the applicant as
described in the NIH Grants
Policy Statement.
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee business official.
Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.
Any application awarded in response to this FOA will be subject to the DUNS, CCR Registration, and Transparency Act requirements as noted on the Award Conditions and Information for NIH Grants website.
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. . More information is provided at Award Conditions and Information for NIH Grants.
The following special terms of award are in addition to, and
not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB)
administrative guidelines, U.S. Department of Health and Human Services (DHHS)
grant administration regulations at 45 CFR Parts 74 and 92 (Part 92 is
applicable when State and local Governments are eligible to apply), and other
HHS, PHS, and NIH grant administration policies.
The administrative and funding instrument used for this program will be the cooperative agreement, an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the awardees is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the award recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the awardees for the project as a whole, although specific tasks and activities may be shared among the awardees and the NIH as defined below.
The PD(s)/PI(s) will have the primary responsibility for:
NIH staff have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:
Areas of Joint Responsibility include:
Dispute Resolution:
Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between award recipients and the NIH may be brought to Dispute Resolution. A Dispute Resolution Panel composed of three members will be convened. The members are: a non-NIH member of the Steering Committee chosen without NIH staff voting, one NIH designee chosen by the NIH Program Director, and a third designee with expertise in the relevant area who is chosen jointly by the Steering Committee and NIH member of the Dispute Resolution Panel. This special dispute resolution procedure does not alter the awardee's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50, Subpart D and DHHS regulation 45 CFR Part 16.
When multiple years are involved, awardees will be required to submit the Non-Competing Continuation Grant Progress Report (PHS 2590) annually and financial statements as required in the NIH Grants Policy Statement.
A final progress report, invention statement, and Financial Status Report are required when an award is relinquished when a recipient changes institutions or when an award is terminated.
The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.
We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.
GrantsInfo (Questions regarding application instructions and
process, finding NIH grant resources)
Telephone: 301-710-0267
Email: email@example.com
eRA Commons Help Desk(Questions regarding eRA Commons
registration, tracking application status, post submission issues)
Phone: 301-402-7469 or 866-504-9552 (Toll Free)
Email: firstname.lastname@example.com
John D. Harding, PhD
National Center for Research Resources (NCRR)
Telephone: 301-435-0776
Email: firstname.lastname@example.com
Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).
Ms. Tiffany M. Walker
National Center for Research Resources (NCRR)
Telephone: 301-435-0839
Email: firstname.lastname@example.com
Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Parts 74 and 92.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Department of Health
and Human Services (HHS)
NIH... Turning Discovery Into Health®
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.


text:
Space Station crew enters Jules Verne ATV
The astronauts on board the International Space Station performed final ATV hatch opening at around 10:30 CEST (08:30 UT) this morning, clearing the way for the crew to start unloading Jules Verne's cargo delivery.
The hatches between ISS and Jules Verne ATV were opened for the first time at around 12:15 CEST (10:15 UT) on Friday, at which time the crew briefly entered ATV to place an air filtering device. The so-called 'air scrubber' was left to run for 8 hours removing any unwanted gasses or small particles of debris that may be floating around.
Immediately after hatch reopening this morning, the lights inside Jules Verne ATV were turned on and the air scrubber dismounted. The crew will now install portable breathing apparatus, a fire extinguisher and the handrails which help the astronauts move around inside ATV. A flexible hose will also be installed to provide additional ventilation. Once all of these items are in place, ATV is ready for full, regular operations
"Everyone here is really pleased with how operations have gone so far, both in space and on the ground. It's a great moment to watch the astronauts going in to ATV - everyone here is happy. Now we will continue to monitor progress," said Alberto Novelli, ESAs head of operations at ATV Control Centre in Toulouse, France
Over the next weeks the crew will remove the 1150 kg of dry cargo delivered by Jules Verne – including fuel, clothes, equipment as well as two original manuscripts handwritten by Jules Verne and a XIXth century illustrated edition of his novel 'From the Earth to the Moon'. In addition the crew will pump 856 kg of propellant, 270 kg of drinking water and 21 kg of oxygen into Zvezda's tanks.
ATV also brings a special gift – a playlist of music selected by Norwegian teenager Therese Miljeteig, the winner of ESA's ATV competition to suggest 10 songs to inspire the astronauts.
Jules Verne will remain attached to as a 48 m3 pressurised and integral part of the complex until early August. When required, ATV will boost the Station's orbit to overcome the effects of residual atmospheric drag. At the end of its mission, Jules Verne ATV will burn up in a controlled reentry into the Earth's atmosphere, and in the process, it will eliminate 6.3 tonnes of waste material no longer needed on the Station and stored over 4 months in the ATV.

subset: commoncrawl